FibroBiologics, Inc. Common Stock (FBLG) Stock Price

FBLGStock
$1.4488.39%52W
Market Cap$9.59M
P/E
PEG Ratio
Div yield
Beta1.70

FBLG Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-85.01%
Price vs S&P 500 (4W)80.62%
VGM Score45.79

FBLG Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.93-$0.66+29.03%(+$0.27)
Q1 2026-$1.35-$1.33+1.85%(+$0.02)
Q4 2025-$2.00-$0.60+70.00%(+$1.40)
Q3 2025-$2.30-$2.60-13.04%(-$0.30)
Q2 2025-$2.25-$2.40-6.67%(-$0.15)

FBLG Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.00
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
FBLGFibroBiologics, Inc. Common Stock
C$1.44
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About FibroBiologics, Inc. Common Stock

FibroBiologics Inc is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. The company's pipeline comprises four candidates: CYWC628, CYPS317, CYMS101, and CybroCell, with additional exploration in oncology and age-related conditions, including novel approaches to reverse thymic involution.